Brentuximab Vedotin Adcetris Injection 50mg
Brentuximab Vedotin Adcetris Injection 50mg DCETRIS (Brentuximab Vedotin) is indicated for treatment of patients with Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates. ADCETRIS (Brentuximab Vedotin) for Injection is supplied as a sterile, white to off-white, preservative-free lyophilized cake or powder in single-dose vials. ADCETRIS is indicated for the treatment of adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.
Brentuximab Vedotin Adcetris Injection 50mg For Sale
Brentuximab vedotin treatment may cause peripheral neuropathy, both sensory and motor. Brentuximab vedotin-induced peripheral neuropathy is typically an effect of cumulative exposure to this medicinal product and is reversible in most cases. In clinical trials, the majority of patients had improvement or resolution of their symptoms (see section 4.8) Patients should be monitored for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paraesthesia, discomfort, a burning sensation, neuropathic pain or weakness. Patients experiencing new or worsening peripheral neuropathy may require a delay and a dose reduction of brentuximab vedotin or discontinuation of treatment, Brentuximab Vedotin Adcetris Injection 50mg
Adcetris 50 MG Injection for Sale
Brentuximab Vedotin 50 mg. (Adcetris) injection is supplied as a sterile, white to off-white preservative-free lyophilized powder or cake in individually boxed for single use vials like 50 mg Brentuximab. Adcetris (Brentuximab Vedotin 50 mg.) has to be stored and transported at 2-8°C (36–46°F) in its original carton to be protected from light. Brentuximab Vedotin (Adcetris) has to be specially handled and to be disposed of as per disposal procedure, as it is an antineoplastic product. Keep medicine out of reach of children.
Brentuximab Vedotin is a cancer medicine that interferes with the growth and spread of cancer cells in the body. (Adcetris) Brentuximab Vedotin is used to treat Hodgkin’s lymphoma or anaplastic large cell lymphoma. Serious infections such as pneumonia, staphylococcal bacteraemia, sepsis/septic shock (including fatal outcomes) and herpes zoster, cytomegalovirus (CMV) (reactivation) and opportunistic infections such as Pneumocystis jiroveci pneumonia and oral candidiasis have been reported in patients treated with brentuximab vedotin. Patients should be carefully monitored during treatment for the emergence of possible serious and opportunistic infections.